What patients take without telling you: Holistic approach for BPH

World Journal of Urology

Volumn 24, Issue 4, 2006, Pages 378-382

  Capodice, Jillian L ^a   Katz, Aaron E ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Benign prostatic hyperplasia (BPH); Herbs

Indexed keywords

ARTICLE; HUMAN; MALE; MEDICINAL PLANT; PHILOSOPHY; PROSTATE HYPERTROPHY;

HOLISTIC HEALTH; HUMANS; MALE; PLANTS, MEDICINAL; PROSTATIC HYPERPLASIA;

EID: 33748124824     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-006-0093-z     Document Type: Article

References (43)

1. Beckman TJ, Mynderse LA (2005) Evaluation and medical management of benign prostatic hyperplasia. Mayo Clin Proc 80(10):1356-1362
2. Kaplan SA (2005) Benign prostatic hyperplasia. J Urol 174(6):2281-2283
3. Lowe FC (2004) Role of the newer alpha, adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther 26(11):1701-1713
4. Brown GA, Sussman DO (2004) A current review of medical therapy for benign prostatic hyperplasia. J Am Osteopath Assoc 104(2 Suppl 2):S11-S16
5. Gunther S, Patterson RE, Kristal AR, Stratton KL, White E (2004) Demographic and health-related correlates of herbal and specialty supplement use. J Am Diet Assoc 104(1):27-34
6. Eng J, Ramsum D, Verhoef M, Guns E, Davison J, Gallagher R (2003) A population-based survey of complementary and alternative medicine use in men recently diagnosed with prostate cancer. Integr Cancer Ther 2(3):212-216
7. Klein EA (2006) Chemoprevention of prostate cancer. Annu Rev Med 57:49-63
8. Dvorkin L, Song KY (2002) Herbs for benign prostatic hyperplasia. Ann Pharmacother 36(9):1443-1452
9. Shoskes DA (2002) Phytotherapy and other alternative forms of care for the patient with prostatitis. Curr Urol Rep 3(4):330-334
10. Shukla S, Gupta S (2005) Dietary agents in the chemoprevention of prostate cancer. Nutr Cancer 53(1):18-32
11. Greenberg JA, Newmann SJ, Howell AB (2005) Consumption of sweetened dried cranberries versus unsweetened raisins for inhibition of uropathogenic Escherichia coli adhesion in human urine: A pilot study. J Altern Complement Med 11(5):875-878
12. Awad AB, Gan Y, Fink CS (2000) Effect of beta-sitosterol, a plant sterol, on growth, protein phosphatase 2A, and phospholipase D in LNCaP cells. Nutr Cancer 36(1):74-78
13. Cabeza M, Bratoeff E, Heuze I, Ramirez E, Sanchez M, Flores E (2003) Effect of beta-sitosterol as inhibitor of 5 alpha-reductase in hamster prostate. Proc West Pharmacol Soc 46:153-155
14. Awad AB, Fink CS, Williams H, Kim U (2001) In vitro and in vivo (SCID mice) effects of phytosterols on the growth and dissemination of human prostate cancer PC-3 cells. Eur J Cancer Prev 10(6):507-513
15. Berges RR, Windeler J, Trampisch HJ, Senge T (1995) Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet 345(8964):1529-1532
16. Klippel KF, Hiltl DM, Schipp B (1997) A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group. Br J Urol 80(3):427-432
17. Berges RR, Kassen A, Senge T (2000) Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: An 18-month follow-up. BJU Int 85(7):842-846
18. Wilt TJ, MacDonald R, Ishani A (1999) beta-sitosterol for the treatment of benign prostatic hyperplasia: A systematic review. BJU Int 83(9):976-983
19. Wilt T, Ishani A, MacDonald R, Stark G, Mulrow C, Lau J (2000) Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev (2):CD001043
20. Medical Economics (ed) (1998) Physician's desk reference (PDR) for herbal medicines. Thomson Healthcare, Montvale
21. Yablonsky F, Nicolas V, Riffaud JP, Bellamy F (1997) Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts. J Urol 157(6):2381-2387
22. Chatelain C, Autet W, Brackman F (1999) Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: A randomized, double-blind study, with long-term open label extension. Urology 54(3):473-478
23. Breza J, Dzurny O, Borowka A, Hanus T, Petrik R, Blane G, Chadha-Boreham H (1998) Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): A multicentre trial in central Europe. Curr Med Res Opin 14(3):127-139
24. Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G (2002) Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev (1):CD001044
25. Anderson ML (2005) A preliminary investigation of the enzymatic inhibition of 5alpha-reduction and growth of prostatic carcinoma cell line LNCap-FGC by natural astaxanthin and Saw Palmetto lipid extract in vitro. J Herb Pharmacother 5(1):17-26
26. Navarrete R, Escribano-Burgos M, Farre AL, Garcia-Cardoso J, Manzarbeitia F, Carrasco C (2005) Serenoa repens treatment modifies bax/ bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. J Urol 173(2):507-510
27. Habib FK, Ross M, Ho CK, Lyons V, Chapman K (2005) Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer 114(2):190-194
28. Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, Lopez Farre A (2003) BPH and inflammation: Pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol 44(5):549-555
29. Debruyne F, Boyle P, Calais Da Silva F, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R, Raynaud JP, Schulman CC (2004) Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis. Eur Urol 45(6):773-779 disucssion 779-780
30. Zlotta AR, Teillac P, Raynaud JP, Schulman CC (2005) Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), tamsulosin or finasteride. Eur Urol 48(2):269-276. Epub 2005
31. Buck AC (2004) Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol 172(5 Pt 1):1792-1799
32. McPartland JM, Pruitt PL (2000) Benign prostatic hyperplasia treated with saw palmetto: A literature search and an experimental case study. J Am Osteopath Assoc 100(2):89-96
33. Wilt T, Ishani A, Mac Donald R (2002) Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev (3):CD001423
34. Konrad L, Muller HH, Lenz C, Laubinger H, Aumuller G, Lichius JJ (2000) Antiproliferative effect on human prostate cancer cells by a stinging nettle root (Urtica dioica) extract. Planta Med 66(1):44-47
35. Sokeland J (2000) Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: Analysis of prostate volume and therapeutic outcome. BJU Int 86(4):439-442
36. Lopatkin N, Sivkov A, Walther C, Schlafke S, Medvedev A, Avdeichuk J, Golubev G, Melnik K, Elenberger N, Engelmann U (2005) Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms - a placebo-controlled, double-blind, multicenter trial. World J Urol 23(2):139-146. Epub 2005
37. Carbajal D, Molina V, Mas R, Arruzazabala ML (2005) Therapeutic effect of d-004, a lipid extract from Roystonea regia fruits, on prostate hyperplasia induced in rats. Drugs Exp Clin Res 31(5-6):193-197
38. Fujita R, Liu J, Shimizu K, Konishi F, Noda K, Kumamoto S, Ueda C, Tajiri H, Kaneko S, Suimi Y, Kondo R (2005) Anti-androgenic activities of Ganoderma lucidum. J Ethnopharmacol 102(1):107-112
39. Shibata Y, Kashiwagi B, Arai S, Fukabori Y, Suzuki K (2005) Administration of extract of mushroom Phellinus linteus induces prostate enlargement with increase in stromal component in experimentally developed rat model of benign prostatic hyperplasia. Urology 66(2):455-460
40. Mannel M (2004) Drug interactions with St John's wort: Mechanisms and clinical implications. Drug Saf 27(11):773-797
41. Singh YN (2005) Potential for interaction of kava and St. John's wort with drugs. J Ethnopharmacol 100(1-2):108-113
42. Bressler R (2005) Herb-drug interactions. Interactions between saw palmetto and prescription medications. Geriatrics 60(11):32-34
43. Miller LG (1998) Herbal medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 158(20):2200-2211